VivoSeq
Other

Transcranial Direct Current Stimulation

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Transcranial Direct Current Stimulation is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

11/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed5 · 56%
Recruiting2 · 22%
Terminated1 · 11%
Unknown status1 · 11%

Clinical Trials

Trial Activity

9 trials

Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM)
Recruiting·HHospital de Clinicas de Porto Alegre·N/A·NCT07203339·610 enrolled
A Machine Learning Approach for Predicting tDCS Treatment Outcomes of Adolescents With Autism Spectrum Disorders
Recruiting·TThe Hong Kong Polytechnic University·Preclinical·NCT05035511·90 enrolled
Cortical Modulation of Acute Post-thoracotomy Pain With Transcranial Direct Current Stimulation
Completed·MMilitary Medical Academy, Belgrade, Serbia·Phase 2·NCT03005548·62 enrolled
Transcranial Direct Current Stimulation for Treating Parkinson´s Disease-related Pain in OFF State
Completed·UUniversidad Francisco de Vitoria·N/A·NCT06214377·15 enrolled
Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation
Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 4·NCT00853866·12 enrolled
Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression
Completed·TThe University of New South Wales·Phase 2·NCT00869765·5 enrolled
Safety and Feasibility of Transcranial Direct Current Stimulation to Enhance Auditory Rehabilitation in Cochlear Implant Recipients
Completed·—·Preclinical·NCT04908631·8 enrolled
The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease
Terminated·NNational Cheng-Kung University Hospital·Phase 1/2·NCT02917122·15 enrolled
Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination
Unknown status·UUniversity of Ottawa·Phase 1/2·NCT02426983·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)